[18F]RO6958948

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Alzheimer's DiseaseAlzheimer's Disease, Healthy Volunteer

Phase 1

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

CompletedNCT02187627

Hoffmann-La RocheAlzheimer's Disease, Healthy Volunteer

Start: 2014-08-31End: 2016-02-29Updated: 2019-01-02

Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants

CompletedNCT02792179

Hoffmann-La RocheAlzheimer's Disease

Start: 2016-07-19End: 2016-09-28Updated: 2017-11-01

Related Papers

P4‐185: First in‐human PET study of 3 novel tau radiopharmaceuticals: [<sup>11</sup>C]RO6924963, [<sup>11</sup>C]RO6931643, and [<sup>18</sup>F]RO6958948

Alzheimer s & Dementia2015-07-0118 citations